BNP Paribas Financial Markets Has $217,000 Stock Position in Agenus Inc. (NASDAQ:AGEN)

BNP Paribas Financial Markets increased its holdings in Agenus Inc. (NASDAQ:AGEN) by 2,271.5% during the third quarter, HoldingsChannel reports. The fund owned 39,533 shares of the biotechnology company’s stock after acquiring an additional 37,866 shares during the quarter. BNP Paribas Financial Markets’ holdings in Agenus were worth $217,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in AGEN. Ovata Capital Management Ltd bought a new stake in Agenus during the 2nd quarter worth approximately $670,000. Federated Hermes Inc. purchased a new position in shares of Agenus during the second quarter valued at approximately $1,921,000. Blair William & Co. IL bought a new stake in Agenus during the second quarter worth $441,000. Point72 DIFC Ltd purchased a new stake in Agenus in the 2nd quarter valued at $51,000. Finally, Squarepoint Ops LLC bought a new position in Agenus during the 2nd quarter valued at $614,000. Institutional investors own 61.46% of the company’s stock.

Agenus Stock Performance

Shares of AGEN stock opened at $2.83 on Tuesday. Agenus Inc. has a 52 week low of $2.50 and a 52 week high of $19.69. The firm’s 50-day simple moving average is $3.77 and its two-hundred day simple moving average is $7.31. The firm has a market cap of $66.39 million, a price-to-earnings ratio of -0.25 and a beta of 1.24.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of Agenus in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, Agenus has an average rating of “Hold” and a consensus price target of $10.00.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.